Allorecognition and the alloresponse: Clinical implications

Tissue Antigens

Volumn 69, Issue 6, 2007, Pages 545-556

  Afzali, B ^a   Lechler, R I ^a,b   Hernandez Fuentes, M P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Allorecognition; Alloresponses; Major histocompatibility complex; Minor histocompatibility antigens; Rejection; T lymphocytes; Transplantation

Indexed keywords

CYTOKINE; IMMUNOSUPPRESSIVE AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MINOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN RECOGNITION; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; ORGAN TRANSPLANTATION; PREGNANCY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ACUTE DISEASE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; GRAFT REJECTION; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; ISOANTIGENS; KILLER CELLS, NATURAL; MICE; MINOR HISTOCOMPATIBILITY ANTIGENS; MODELS, IMMUNOLOGICAL; TRANSPLANTATION IMMUNOLOGY;

EID: 34248335371     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00834.x     Document Type: Review

References (100)

1. Nyholm SV, Passegue E, Ludington WB et al. fester, A candidate allorecognition receptor from a primitive chordate. Immunity 2006:25:163 73.
2. Rinkevich B. Primitive immune systems: are your ways my ways? Immunol Rev 2004:198:25 35.
3. Whitelegg AM, Oosten LE, Jordan S et al. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J Immunol 2005:175:1706 14.
4. Ford D, Burger D. Precursor frequency of antigen-specific T cells: effects of sensitization in vivo and in vitro. Cell Immunol 1983:79:334 44.
5. Lombardi G, Sidhu S, Batchelor JR, Lechler RI. Allorecognition of DR1 by T cells from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides. Proc Natl Acad Sci USA 1989:86:4190 4.
6. Warrens AN, Lombardi G, Lechler RI. Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 1994:2:103 7.
7. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982:155:31 41.
8. Herrera OB, Golshayan D, Tibbott R et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004:173:4828 37.
9. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler RI. The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001:72:480 5.
10. Schneck J, Munitz T, Coligan JE, Maloy WL, Margulies DH, Singer A. Inhibition of allorecognition by an H-2Kb-derived peptide is evidence for a T-cell binding region on a major histocompatibility complex molecule. Proc Natl Acad Sci USA 1989:86:8516 20.
11. Villadangos JA, Galocha B., Lopez de Castro JA. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. J Immunol 1994:152:2317 23.
12. Lombardi G, Barber L, Sidhu S, Batchelor JR, Lechler RI. The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and which influence peptide binding. Int Immunol 1991:3:769 75.
13. Smith PA, Brunmark A, Jackson MR, Potter TA. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med 1997:185:1023 33.
14. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993:11:385 402.
15. Weber DA, Terrell NK, Zhang Y et al. Requirement for peptide in alloreactive CD4+ T cell recognition of class II MHC molecules. J Immunol 1995:154:5153 64.
16. Eckels DD, Gorski J, Rothbard J, Lamb JR. Peptide-mediated modulation of T-cell allorecognition. Proc Natl Acad Sci USA 1988:85:8191 5.
17. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990:11:83 8.
18. Dalchau R, Fangmann J, Fabre JW. Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules. Evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol 1992:22:669 77.
19. Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997:64:795 800.
20. Fangmann J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992:175:1521 9.
21. Sayegh MH, Perico N, Imberti O, Hancock WW, Carpenter CB, Remuzzi G. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. Transplantation 1993:56:461 5.
22. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996:183:699 703.
23. Game DS, Rogers NJ, Lechler RI. Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells. Am J Transplant 2005:5:1614 25.
24. Morelli AE, Larregina AT, Shufesky WJ et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004:104:3257 66.
25. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H Jr. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994:179:865 72.
26. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998:161:5813 6.
27. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A novel pathway of antigen presentation by dendritic and endothelial cells: Implications for allorecognition and infectious diseases. Transplantation 2006:82 (Suppl S15 S18.
28. Tsang JY, Chai JG, Lechler R. Acquisition of MHC:peptide complexes by mouse CD4+ T cells may play a role in T-cell-mediated immunoregulation. Transplant Proc 2002:34:2849 50.
29. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001:166:3789 96.
30. Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005:65:301 69.
31. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006:24:419 66.
32. Abbas AK, Lichtman AH. The Major Histocompatibility Complex. Cellular and Molecular Immunology, 5th edn, updated edn. Philadelphia: Elsevier Saunders, 2005.
33. Bozzacco L, Trumpfheller C, Siegal FP et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007:104:1289 94.
34. Borg NA, Ely LK, Beddoe T et al. The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. Nat Immunol 2005:6:171 80.
35. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994:91:6259 63.
36. Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999:60:323 30.
37. Zhang Y, Stastny P. MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity. Hum Immunol 2006:67:215 22.
38. Glotz D, Lucchiari N, Pegaz-Fiornet B, Suberbielle-Boissel C. Endothelial cells as targets of allograft rejection. Transplantation 2006:82 (Suppl S19 S21.
39. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007:7:408 15.
40. Barth R, Counce S, Smith P, Snell GD. Strong and weak histocompatibility fine differences in mice and their role in the rejection of homografts of tumors and skin. Ann Surg 1956:144:198 204.
41. Simpson E, Scott D, James E et al. Minor H antigens: genes and peptides. Transpl Immunol 2002:10:115 23.
42. Yoshimura Y, Yadav R, Christianson GJ, Ajayi WU, Roopenian DC, Joyce S. Duration of alloantigen presentation and avidity of T cell antigen recognition correlate with immunodominance of CTL response to minor histocompatibility antigens. J Immunol 2004:172:6666 74.
43. Simpson E, Roopenian D, Goulmy E. Much ado about minor histocompatibility antigens. Immunol Today 1998:19:108 12.
44. Simpson E. Minor transplantation antigens: animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions. Transplantation 1998:65:611 6.
45. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003:197:1279 89.
46. Piper KP, McLarnon A, Arrazi J et al. Functional HY-specific CD8+ T cells are found in a high proportion of women following pregnancy with a male fetus. Biol Reprod 2007:76:96 101.
47. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 2006:67:433 8.
48. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983:302:159 61.
49. Loveland B, Wang CR, Yonekawa H, Hermel E, Lindahl KF. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell 1990:60:971 80.
50. Bhuyan PK, Young LL, Lindahl KF, Butcher GW. Identification of the rat maternally transmitted minor histocompatibility antigen. J Immunol 1997:158:3753 60.
51. Ishikawa Y, Kashiwase K, Okai M et al. Polymorphisms in the coding region of mtDNA and effects on clinical outcome of unrelated bone marrow transplantation. Bone Marrow Transplant 2001:28:603 7.
52. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002:190:40 52.
53. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002:295:2097 100.
54. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006:214:202 18.
55. Vilches C, Parham P. Do NK-cell receptors and alloreactivity affect solid organ transplantation? Transpl Immunol 2006:17:27 30.
56. Le MA, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002:73:1373 81.
57. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003:3:665 73.
58. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 and regulatory T cells in human disease. Clin Exp Immunol 2007:[Epub ahead of print].
59. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006:19:87 97.
60. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994:153:3791 803.
61. Baumann BC, Stussi G, Huggel K, Rieben R, Seebach JD. Reactivity of human natural antibodies to endothelial cells from Galalpha(1, 3)Gal-deficient pigs. Transplantation 2007:83:193 201.
62. Scornik JC, Salomon DR, Howard RJ, Pfaff WW. Evaluation of antibody synthesis in broadly sensitized patients. Transplantation 1988:451:95 100.
63. Gallon LG, Leventhal JR, Kaufman DB. Pretransplant evaluation of renal transplant candidates. Semin Nephrol 2002:22:515 25.
64. Ibrahim S, Dawson DV, Sanfilippo F. Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995:59:724 8.
65. Matheson PJ, Dittmer ID, Beaumont BW, Merrilees MJ, Pilmore HL. The macrophage is the predominant inflammatory cell in renal allograft intimal arteritis. Transplantation 2005:79:1658 62.
66. Hoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005:5:573 81.
67. Krieger NR, Ito H, Fathman CG. Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice. J Autoimmun 1997:10:309 15.
68. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003:349:2288 90.
69. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999:55:713 23.
70. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003:349:2326 33.
71. Libby P, Pober JS. Chronic rejection. Immunity 2001:14:387 97.
72. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004:4:438 43.
73. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006:81:643 54.
74. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 1995:270:630 3.
75. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J 2005:19:681 93.
76. Hunt JS. Stranger in a strange land. Immunol Rev 2006:213:36 47.
77. Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996:184:539 48.
78. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006:132:217 32.
79. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998:281:1191 3.
80. Guleria I, Khosroshahi A, Ansari MJ et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005:202:231 7.
81. Makrigiannakis A, Zoumakis E, Kalantaridou S et al. Corticotropin- releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol 2001:2:1018 24.
82. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004:5:266 71.
83. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997:23:195 212.
84. Bianchi DW. Fetomaternal cell trafficking: a new cause of disease? Am J Med Genet 2000:91:22 8.
85. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999:285:412 5.
86. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001:29:259 77.
87. Friedman TM, Jones SC, Statton D, Murphy GF, Korngold R. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 2004:10:224 35.
88. Hirokawa M, Matsutani T, Saitoh H et al. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation. Bone Marrow Transplant 2002:30:915 23.
89. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996:334:281 5.
90. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987:67:397 406.
91. Schmitz N, Eapen M, Horowitz MM et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006:108:4288 90.
92. Smith DM, Agura E, Netto G et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003:75:118 26.
93. Mazariegos GV, bu-Elmagd K, Jaffe R et al. Graft versus host disease in intestinal transplantation. Am J Transplant 2004:4:1459 65.
94. Smith DM, Agura ED, Ausloos K, Ring WS, Domiati-Saad R, Klintmalm GB. Graft-vs-host disease as a complication of lung transplantation. J Heart Lung Transplant 2006:25:1175 7.
95. Weinstein A, Dexter D, KuKuruga DL, Philosophe B, Hess J, Klassen D. Acute graft-versus-host disease in pancreas transplantation: a comparison of two case presentations and a review of the literature. Transplantation 2006:82:127 31.
96. Smith DM, Agura ED, Levy MF, Melton LB, Domiati-Saad R, Klintmalm G. Graft vs host disease following kidney transplantation using an '0 HLA antigen mismatched' donor. Nephrol Dial Transplant 2006:21:2656 9.
97. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002:196:389 99.
98. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999:189:1073 81.
99. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002:196:401 6.
100. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999:94:1201 8.